Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an announcement.
Shanghai Junshi Biosciences Co., Ltd. announced that its investigational new drug application for JS212 injection has been accepted by the National Medical Products Administration. JS212 is a bispecific antibody-drug conjugate targeting EGFR and HER3, showing promise in treating advanced malignant solid tumors and overcoming drug resistance. This acceptance marks a significant advancement for the company in its drug development pipeline, potentially enhancing its position in the oncology pharmaceutical market.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company based in China, focusing on the research, development, and production of innovative drugs. It specializes in developing antibody-drug conjugates and other advanced therapies for treating various types of cancer.
YTD Price Performance: -3.80%
Average Trading Volume: 1,369,638
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$24.18B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- 3 Penny Stocks to Watch Now, 1/9/25
- M&A News: Arm Holdings Explores Possible Takeover of Ampere Computing
- M&A News: Constellation Energy’s $30B Calpine Takeover Takes Shape
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
